Multi-outcome AI-ECG risk-estimation platform that turns a single 12-lead ECG into a patient-specific survival curve, using a residual convolutional neural network trained with a discrete-time survival loss to predict not just risk but time-to-event. Beyond all-cause and cardiovascular mortality, separately fine-tuned heads predict future ventricular arrhythmia, complete heart block, atrial fibrillation, atherosclerotic cardiovascular disease, heart failure, and (in follow-up work) hypertension -- all from a single resting ECG, including in ECGs a cardiologist would read as normal. Derived on 1.16 million ECGs from 189,539 Beth Israel Deaconess Medical Center patients and externally validated across transnational cohorts in the USA, Brazil (CODE), and the UK (UK Biobank). A variational autoencoder and genome/phenome-wide association analyses were used to show the model's predictions track biologically plausible features (QRS morphology, LV structure/function, and loci linked to cardiac structure, QT interval, and biological aging). NHS trials of AIRE were planned for late 2025. No public code or model weights have been released.

1D residual neural network that predicts a patient's age directly from a 12-lead ECG; the gap between this predicted 'ECG age' and true chronological age is used as a biomarker of cardiovascular risk and mortality. Trained on the CODE-15% Brazilian ECG dataset, with the original R² of 0.71 later reproduced (R² = 0.70) in an independent German validation cohort. Developed by researchers at Uppsala University and UFMG.

Multi-task 12-lead ECG model with output heads for incident atrial-fibrillation risk (as a survival curve), incident mortality risk, prevalent AF classification, sex classification, and age regression. Built on a 1D CNN over the raw waveform, and developed by the Broad Institute's ML4H group as a successor to their ECG-AI model published in Circulation. Trained on ECGs from UK Biobank and Massachusetts General Hospital, neither of which is publicly released.